Please login to the form below

Not currently logged in
Email:
Password:

bevacizumab

This page shows the latest bevacizumab news and features for those working in and with pharma, biotech and healthcare.

AZ and Clovis PARP inhibitors show their mettle at ESMO

AZ and Clovis PARP inhibitors show their mettle at ESMO

AZ and MSD are also trialling Lynparza alongside Roche’s Avastin (bevacizumab) in this broader patient group.

Latest news

  • Ocrevus surge keeps Roche smiling in Q3 Ocrevus surge keeps Roche smiling in Q3

    The third of Roche’s ‘big-three’antibody blockbusters – cancer therapy Avastin (bevacizumab) – also rose 2% with gains in international markets propping up flat US sales and a decline in Europe.

  • Keytruda hits survival targets in first-line kidney cancer Keytruda hits survival targets in first-line kidney cancer

    with its IMmotion 151 study comparing PD-L1 inhibitor Tecentriq (atezolizumab) plus Avastin (bevacizumab) to Sutent, which showed positive effects on PFS at this year’s ASCO meeting.

  • First Humira biosimilars reach EU market First Humira biosimilars reach EU market

    For Amgen it is its second biosimilar product approval in Europe after Mvasi (bevacizumab), a version of Roche’s cancer drug Avastin.

  • Bayer to challenge Avastin legal ruling Bayer to challenge Avastin legal ruling

    A week ago the UK’s High Court ruled that it was lawful for local NHS Clinical Commissioning Groups (CCGs) to offer patients Avastin (bevacizumab) injections for the treatment of wet ... Bayer says its appeal will focus on two principal issues, firstly

  • Roche’s Tecentriq misses survival mark in frontline NSCLC Roche’s Tecentriq misses survival mark in frontline NSCLC

    Meanwhile, Roche suffered another knockback earlier this month when its US application for a first-line combination for non-squamous NSCLC based on Tecentriq, its older cancer antibody Avastin (bevacizumab) and

More from news
Approximately 25 fully matching, plus 186 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • The Biosimilar Challenge

    These include the infliximab biosimilars Inflectra and Remsima, the etanercept biosimilar Benepali (launched last year) and biosimilars to adalimumab, filgrastim and bevacizumab preparing to launch on the horizon.

  • The Biosimilar Challenge

    These include the infliximab biosimilars Inflectra and Remsima, the etanercept biosimilar Benepali (launched last year) and biosimilars to adalimumab, filgrastim and bevacizumab preparing to launch on the horizon.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics